{
  "id": "n_myc_amplification_57417",
  "algorithm": "pediatric",
  "version": "1.0",
  "name": "n-MYC Amplification",
  "title": "n-MYC Amplification",
  "notes": "**Note 1:** This SSDI is effective for diagnosis years 2024+\n* For cases diagnosed 2018-2023, leave this SSDI blank\n\n**Note 2:** n-MYC Amplification is a gene that normally regulates cell growth. Studies have shown that n-MYC amplification is an indicator of poor prognosis and increased risk of unfavorable outcomes in patients with neuroblastoma.\n* Primary sources of information: molecular pathology report (may be addendum to original pathology report), CAP Protocol\n\n**Note 3:** Physician statement of n-MYC can be used to code this data item when no other information is available.",
  "footnotes": "(1) American Society of Clinical Oncology Â© 2009, The International Neuroblastoma Risk Group (INRG) Classification System: AN INRG Task Force Report; published by American Society of Clinical Oncology, 2009",
  "last_modified": "2023-08-17T00:18:18.012Z",
  "definition": [
    {
      "key": "n_myc_amplification",
      "name": "Code",
      "type": "INPUT"
    },
    {
      "key": "description",
      "name": "Description",
      "type": "DESCRIPTION"
    }
  ],
  "rows": [
    [
      "0",
      "Not amplified"
    ],
    [
      "1",
      "Amplified"
    ],
    [
      "2",
      "Gain"
    ],
    [
      "7",
      "Test ordered, results not in chart"
    ],
    [
      "8",
      "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error)"
    ],
    [
      "9",
      "Not documented in medical record\nCannot be determined by pathologist\nNot applicable (secondary to previous chemotherapy)\nn-MYC not assessed or unknown if assessed"
    ],
    [
      "",
      "N/A - Diagnosis year is prior to 2024"
    ]
  ]
}